Is Regeneron Pharmaceuticals, Inc. (REGN) undervalued or overvalued?

Our model estimates a fair value of about $920 against a price of $790.74 (Fair, +16% to fair value). It blends a 10-year DCF, sector multiples and earnings-power value and is a model estimate, not advice.

What is the X-Ray Score for REGN?

Regeneron Pharmaceuticals, Inc. has an X-Ray Score of 50 out of 100, built from valuation, growth, profitability, financial health and dividend lenses ranked against Health Care peers.

Where does the data for REGN come from?

Financial statements come from SEC EDGAR filings, prices from exchange price feeds, and industry betas and equity risk premium from Damodaran Online (NYU Stern).

Regeneron Pharmaceuticals, Inc. (REGN)

Health Care · Biotechnology · US stock · S&P 500 component

$790.74 ▼ -5.60 (0.70%)

At close 16 Oct 2026 · USD · Volume 653,500

Compare with INCY Historical data Research report SEC filings

Fair valueFair

$920 +16.3% to fair value

$460fair band $552–$1,288$1,380

Day's range

$787.32 – $805.68

52-week range

$561.12 – $859.34

About Regeneron Pharmaceuticals, Inc.

Regeneron is a biotechnology company that discovers, develops and commercialises medicines for serious diseases. Its marketed products include Eylea for eye conditions and Libtayo for certain cancers, and it shares in the Dupixent antibody medicine developed with Sanofi, which treats several inflammatory conditions. Much of its research relies on its own antibody technology platforms. It supplies hospitals, clinics and specialty providers through distributors and works with partner companies on development.

Revenue comes from product sales and from collaboration income, including its share of Dupixent profits. Sales were $15.5 billion over the last twelve months, up 5.6% a year over the last three years, with an operating margin of 24.7%. The business earns a profit of 13% on the capital invested in it and has net debt of -1.4 times EBITDA, meaning it holds more cash than debt. A dividend is paid, with a yield of 0.5%. On the site's X-Ray Score it receives 50 out of 100.

Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.

Price chart

Historical data & CSV

52-wk range $561.12 – $859.34Volume 653,500Daily, split-adjusted

Vitals

Market cap$83.8B

52-week range$561.12 – $859.34

Volume (last day)653,500

P/E (TTM)19.6

EBIT / EV yield4.9%

Free-cash-flow yield4.5%

Dividend yield0.5%

Revenue (TTM)$15.5B

Net income (TTM)$4.3B

Operating margin24.7%

Return on capital12.5%

Debt incl. leases$2.0B

Cash & securities$8.0B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$920model spread $890 – $955

Fair +16.3% to fair value

Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.

Price $791

Undervalued < $552Fair $552 – $1,288Overvalued > $1,288

10-year DCF (market-scaled)

$865

Peer multiples

$941

Earnings power floor (not blended)

$512

Fundamentals-adjusted multiple

$954

Growth the price implies

16.3%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.

What this means

Average business, fairly priced

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better ✓ 54 The price is not above fair value $920 fair value Debt looks manageable -1.4× EBITDA Revenue has been growing 5.6% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Valuation Fair

63/100

Priced about in line with its sector.

See the numbers →

EBIT / EV yield4.9%

Free-cash-flow yield4.5%

Fair value vs price1.2×

Growth Weak

34/100

Growing slower than most of its sector.

See the numbers →

Revenue growth (3y)5.6%

EPS growth (3y)2.8%

Growth consistency80%

Profitability Weak

37/100

Earns lower returns on its capital than most peers.

See the numbers →

Return on invested capital12.5%

Operating margin24.7%

Financial health Strong

72/100

Balance sheet looks strong: debt is well covered.

See the numbers →

Piotroski F-Score5 / 9

Net debt / EBITDA-1.4×

Interest coverNo interest cost

Dividends Weak

40/100

Dividend is modest or less certain than peers.

See the numbers →

Dividend yield0.5%

Dividends vs free cash flow10%

Quarterly results: last 6 quarters

-3.7%

Mar '25

+3.6%

Jun '25

+0.9%

Sep '25

+2.5%

Dec '25

+19.0%

Mar '26

+16.7%

Jun '26

Revenue against the same quarter a year earlier. Latest quarter revenue $4.3B, diluted EPS $12.23.

Compare with peers

INCY Incyte Corp81 VRTX Vertex Pharmaceuticals...55 AMGN Amgen Inc51 BIIB Biogen Inc.47

Other Biotechnology companies by X-Ray Score.

Fundamentals checklist

● 6 Good · ● 6 Average · ● 3 Bad

Cash quality

Earnings backed by cashBad

Free-cash-flow yieldAverage

Risk models

Altman Z''Good

Piotroski F-ScoreBad

Growth

EPS growth (3y)Average

Free-cash-flow growth (3y)Average

Revenue growth (3y)Average

Growth consistencyBad

Balance sheet

Current ratioGood

Net debt / EBITDAGood

Interest coverGood

Valuation

Fair value vs priceGood

EBIT / EV yieldAverage

Profitability

Return on invested capitalAverage

Operating marginGood

Each check is graded against the company's sector, not a fixed number. Checklist score 57/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$16.1B	$12.2B	$13.1B	$14.2B	$14.3B
Operating income	$8.9B	$4.7B	$4.0B	$4.0B	$3.6B
Net income	$8.1B	$4.3B	$4.0B	$4.4B	$4.5B
Operating cash flow	$7.1B	$5.0B	$4.6B	$4.4B	$5.0B
Operating margin	55.7%	38.9%	30.9%	28.1%	24.9%
Free cash flow	$6.5B	$4.4B	$3.9B	$3.7B	$4.1B
Diluted EPS	$71.97	$38.22	$34.77	$38.34	$41.48

Fiscal years, from SEC filings.

Technical summary

Daily

Strongly bullish

11 bullish · 4 neutral · 1 bearish

Weekly

Strongly bullish

11 bullish · 1 neutral · 0 bearish

Monthly

Strongly bullish

7 bullish · 1 neutral · 0 bearish

Moving averages (daily)

SMA 10	757.5	Bullish
EMA 10	768.6	Bullish
SMA 20	764.7	Bullish
EMA 20	768.2	Bullish
SMA 50	790.7	Bullish
EMA 50	765.8	Bullish
SMA 100	721.8	Bullish
EMA 100	748.2	Bullish
SMA 200	734.1	Bullish
EMA 200	727.7	Bullish

Oscillators (daily)

RSI (14)	57.18	Neutral
MACD (12, 26)	-2.25	Bearish
Momentum (12)	4.28	Bullish
Stochastic %K (14)	78.56	Neutral
Williams %R (14)	-21.44	Neutral
CCI (20)	84.75	Neutral

Pivot points (classic, last session)

765.1

776.2

783.5

Pivot

794.6

801.8

812.9

820.2

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.